Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Completed · Phase 1
Conditions studied: Diabetes Mellitus, Insulin-Dependent
In brief
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
Key facts
- Study ID
- NCT00073255
- Run by
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- People needed
- 12
- Starts
- 2003-06-01
- Expected to finish
- 2005-12-01
- Last updated by the study team
- 2010-01-15
Who can join
Age: 8 and older, up to 30. Sex: any. Healthy volunteers: accepted.
Where it is running
- Columbia University — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.